Merck & Co., Inc. has reported detailed Phase 3 data showing that enlicitide decanoate, its investigational once-daily oral proprotein convertase subtilisin/kexin type 9 inhibitor, achieved significantly greater low-density lipoprotein cholesterol reductions at eight weeks than bempedoic acid, ezetimibe, or the combination of bempedoic acid with ezetimibe when added to background statin therapy in adults with hypercholesterolemia and established or at-risk atherosclerotic cardiovascular disease. The late-breaking CORALreef AddOn results, presented at ACC.26 and published in the Journal of the American College of Cardiology, add a third positive pivotal Phase 3 study to the program and strengthen the case for what could become the first approved oral PCSK9 inhibitor.

Why Merck’s enlicitide decanoate could shift oral cholesterol management beyond incremental add-on therapy

What makes these data commercially and clinically relevant is not simply that enlicitide lowered LDL-C more than established oral comparators. The bigger implication is that Merck is trying to reposition PCSK9 inhibition from a powerful but underutilized category into something closer to a scalable mainstream option. Injectable PCSK9 monoclonal antibodies have already shown that this mechanism can deliver substantial LDL-C lowering, but uptake in routine care has been held back by a mix of access hurdles, payer controls, treatment complexity, and plain old human behavior. A daily pill does not automatically erase those barriers, but it directly targets one of the category’s biggest structural weaknesses: friction.

In CORALreef AddOn, enlicitide cut LDL-C by 64.6% from baseline at eight weeks on top of statins, while also outperforming bempedoic acid by 56.7%, ezetimibe by 36.0%, and bempedoic acid plus ezetimibe by 28.1%. Those are not marginal differences dressed up as progress. They suggest that Merck is not merely offering another oral add-on in a crowded lipid-management sequence. It is attempting to create a pill-based option with efficacy closer to injectable biologics than to the oral step-up agents that currently sit between statins and more intensive therapy. That distinction matters because clinicians do not need another modest LDL-C reducer as much as they need a practical way to get harder-to-treat patients to target.

What the CORALreef AddOn data reveal about the growing pressure on existing oral non-statin treatments

Why this matters for the treatment landscape is that the existing oral non-statin pathway has always been useful but imperfect. Ezetimibe is easy to use and familiar, but its LDL-C effect is relatively modest. Bempedoic acid broadened the oral toolkit, especially for statin-intolerant or undertreated patients, but it still does not usually deliver the sort of reduction associated with PCSK9-targeting therapies. Merck’s data therefore point to a possible shift in treatment sequencing. If enlicitide reaches market with a competitive label, clean tolerability, and manageable reimbursement terms, clinicians may begin to see oral therapy not as a slower ladder toward injectables, but as a way to access biologic-like potency without crossing into injection-based care.

What this reveals about the strength of the evidence is that CORALreef AddOn was designed to answer a practical question rather than a purely theoretical one. It was a randomized, double-blind, multicenter Phase 3 study comparing enlicitide directly against real oral alternatives in statin-treated adults with hypercholesterolemia and cardiovascular risk. That comparator design gives the dataset more commercial and clinical relevance than a placebo-controlled win alone would have done. Merck is effectively saying that enlicitide should not just work in principle. It should outperform the actual pills clinicians prescribe when statins are not enough. For industry observers, that is a more useful signal than another placebo-separated efficacy result.

Why an oral PCSK9 inhibitor may matter more for treatment access and adherence than for efficacy alone

Still, the study’s time horizon is also its biggest interpretive limitation. Eight-week LDL-C data are meaningful, especially in lipid-lowering trials where biomarker change is a central regulatory currency, but they do not settle the longer-term questions that will determine whether enlicitide becomes a practice-changing product or an interesting niche entrant. Durability, persistence, real-world adherence outside a tightly run trial, and eventual cardiovascular outcomes remain the tests that matter most. Merck has emphasized that the large CORALreef Outcomes trial has completed enrollment with over 14,500 participants, and that is where the mechanistic promise will have to convert into hard-event credibility.

What clinicians and payers are likely to watch next is not just whether enlicitide lowers LDL-C, but whether it changes the economics and logistics of escalation. High adherence figures in CORALreef AddOn, including 98% adherence to study intervention and at least 96% adherence to dosing instructions, are encouraging, but trial adherence is often cleaner than what happens after launch. A daily pill sounds simpler than an injection, yet daily treatment also introduces its own behavioral challenge. Injectable products, paradoxically, sometimes benefit from less frequent dosing because patients do not have to remember them every day. That means the oral advantage is real, but not automatic. The commercial winner will be the product that combines potency, convenience, coverage, and persistence, not just the one that produces the best conference-slide headline.

Another noteworthy aspect of the dataset is that enlicitide also improved secondary lipid markers, with significant reductions in apolipoprotein B and non-high-density lipoprotein cholesterol, while showing a reduction in lipoprotein(a) that compared favorably with the oral alternatives. Those readouts strengthen the argument that this is not a one-dimensional LDL-C story. Even so, the company’s own framing makes clear that some of these measures were non-multiplicity-controlled, so they should be interpreted as supportive rather than definitive. Industry and regulatory watchers will likely view them as additive evidence of mechanistic breadth, but not as a substitute for robust outcomes evidence or long-term differentiated labeling.

What still stands between strong LDL-C lowering data and broader real-world adoption in lipid care

The safety narrative, at least at this stage, is supportive. Merck said the overall profile was consistent with the earlier Phase 3 CORALreef Lipids and CORALreef HeFH trials, with no clinically meaningful differences in adverse event incidence across treatment groups and no serious adverse events or drug-related discontinuations among those treated with enlicitide in this study. That matters because oral therapies seeking broad cardiometabolic use do not have much room for tolerability compromise. In a category where many patients are asymptomatic and treatment goals are preventive, even modest safety or tolerability concerns can quickly become adoption brakes.

The regulatory setup also looks more favorable than it did a year ago. Merck noted that enlicitide received the United States Food and Drug Administration’s Commissioner’s National Priority Voucher in December 2025, a signal that may help accelerate review. That does not guarantee approval, and it certainly does not answer post-approval market access questions, but it does suggest that regulators see enough public-health importance in the program to move it through a faster lane. For Merck, that matters strategically because being first with an oral PCSK9 inhibitor could create category-defining leverage even before cardiovascular outcomes data fully mature.

Why cardiovascular outcomes, payer positioning, and long-term persistence will define enlicitide’s commercial future

This is where the competitive picture becomes more interesting. Enlicitide is not merely a cholesterol product in development. It is an attempt to redraw the boundary between primary oral escalation therapy and injectable specialist-grade intensification. If Merck succeeds, the ripple effects could extend beyond one brand. It could pressure established oral non-statin therapies, influence guideline discussions around treatment sequencing, and reopen commercial interest in mechanisms that were previously viewed as too cumbersome to expand beyond selected high-risk populations. In other words, the opportunity is not just substitution. It is category expansion.

The unanswered question is whether the product can deliver that expansion without running into the classic traps of cardiometabolic launches. Reimbursement negotiations may still position enlicitide behind cheaper oral options. Outcomes data are still pending. Real-world adherence may be less pristine than trial adherence. And clinicians may remain conservative until longer-duration evidence clarifies where the drug best fits relative to ezetimibe, bempedoic acid, and injectable PCSK9 agents. So while the CORALreef AddOn result is clearly important, it should be read as a strong platform-building dataset rather than a final verdict.

That is the real takeaway from Merck’s update. The U.S.-based pharmaceutical group has moved enlicitide beyond the stage of being an interesting formulation story and closer to becoming a serious strategic challenger in lipid management. The data suggest oral PCSK9 inhibition is no longer just a clever idea hunting for proof. It is now a credible late-stage proposition. But the leap from credible proposition to routine standard of care will depend on what happens next in outcomes, access, and execution.

  atherosclerotic cardiovascular disease, cardiometabolic disease, CORALreef AddOn, enlicitide decanoate, hypercholesterolemia, Inc., lipid management, low-density lipoprotein cholesterol, Merck & Co., PCSK9 inhibitor